jnj-77242113
janssen
['psoriasis', 'frontier 1']
an investigational il-23r antagonist demonstrated significantly greater efficacy across all doses in patients with moderate to severe #psoriasis compared with placebo at week 16 in the frontier 1 study. #wcd2023singapore #wcd2023 
Medscape provides breaking medical news and expert perspectives, drug and disease information, and free CME across 30+ medical specialties.